You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Allosteric Drug Discovery using Quantum Cascade Laser based Anisotropic THz Microscope (QCL-ATM)
SBC: LONGWAVE PHOTONICS LLC Topic: 400Allosteric Drug Discovery using Quantum Cascade Laserbased Anisotropic THz Microscope (QCL-ATM) Proposal in Response to NIH/NIGMS STTR PA-20-265 This STTR will result in a commercially viable instrument that will enable critical research in allosteric drugs and protein dynamics. To date allosteric inhibitors are largely found serendipitously. Anisotropic THz microspectroscopy (ATM) uniquely measur ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Translation of Interferometric-based Free-solution Assay Methodology
SBC: MERU BIOTECHNOLOGIES Topic: 300Project Summary: Lung cancer is the leading cause of cancer-related deaths in the United States. Low dose chest computed tomography (CT) screening programs that target high-risk individuals can reduce lung cancer-specific mortality by 20% and overall mortality by 6.9%. There is a growing movement to implement this life saving screening into routine practice, with endorsements from the U.S. Prevent ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of Melanocortin-3 Receptor Peptide Agonists for the Treatment of Anorexia Nervosa
SBC: COURAGE THERAPEUTICS INC Topic: 101Anorexia nervosa (AN) is a devastating neuropsychiatric disease with a high prevalence (up to 2.2% of women) and significant morbidity and mortality. There are currently no effective therapeutic agents for the disorder. The goal of Courage Therapeutics is the development of melanocortin-3 receptor (MC3R) -specific agonist peptides for the treatment of anorexia nervosa. The product of this Phase I ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Developing a novel drug for neurobehavioral deficits in FASD
SBC: COGTHERA LLC Topic: 230Project Summary Fetal Alcohol Spectrum Disorder (FASD) is a debilitating condition causing a wide range of disabilities including behavioral and intellectual deficits, facial dysmorphology, and organ malformations. This disorder has a profound impact on health care burden and cost; as many as 5% of children within the United States are affected by this condition, with lifetime treatment costs reac ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Multistage LC-MSn for automated glycan isomer assignment of glycopeptides
SBC: PROTEIN METRICS INC Topic: 400N- and O-linked glycosylation are some of the most common, abundant, and biologically important posttranslational modifications of proteins, yet they are also some of the most difficult to study. The dominant analytical platform for the study of glycosylation is mass spectrometry, yet this platform on its own is incomplete, because it cannot elucidate glycan topology and linkage stereochemistry. T ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Rapid point-of-care detection of Chlamydia trachomatis in urine
SBC: ELECTRONUCLEICS INC Topic: NIAIDProject Summary The goal of this project is to demonstrate feasibility of a system for the point-of-care (POC) detection of Chlamydia trachomatis (CT) in human urine samples that integrates a patented detector of pathogens based on identification of species-specific, nucleic acid (NA) sequences. The detector relies on a novel electromechanical signal transduction mechanism that enables the low-cos ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Polymer use in Preservation of Tissue Perfusion to Address Sepsis
SBC: PERFUSION MEDICAL LLC Topic: 300Perfusion Medical is commercializing a novel pipeline product called PEG-20k IV Solution. The company believes this may be the first therapeutic to directly treat lethal complications of sepsis, and as such, support new thinking on the basic mechanisms of the disease. Sepsis or septic syndrome leads to a spectrum of illnesses and occurs at a frequency of 1.7 million people in the US each year and ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Eliminating Acne Through Photo-Inactivation Catalase
SBC: PULSETHERA CORP Topic: NIAMSPROJECT SUMMARYAcne vulgaris is a skin inflammatory condition affecting 80% of young adults and can frequently induce permanent disfigurement even with appropriate treatment. Acne is caused by C. acnes in the setting of hormonal changes and sebum induction that accompany adolescence. The mainstay of therapeutics consist of eradicating C. acnes and reducing inflammation. However, treatment is prolo ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment
SBC: ZYMO RESEARCH CORP. Topic: NINDSPROJECT SUMMARY/ABSTRACT Stroke injury occurs over a long duration through pathologic changes leading to long-term neurologic dysfunction. There is an urgent need of therapeutic strategies that can provide safe and efficacious therapeutic effects to the hypoperfused brain with long-lasting endogenous neuroprotection for prevention of long-term neurologic dysfunction. Sufficient evidence has pointe ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
A Transparent Surgical Mask to Improve Patient/Caregiver Communication, Minimize Errors and Increase Patient Satisfaction
SBC: FaceView Mask, LLC Topic: NINRPROJECT SUMMARY Approximately 4% of people in the US are either deaf or hard of hearing, equating to more than 13 million people. Of these, approximately 12 million people over the age of 5 years have difficulty hearing normal conversation even when using a hearing aid. Hearing difficulties affect all age groups and present significant challenges in daily life. These challenges are particularly ac ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health